FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894030992> ?p ?o ?g. }

• W2894030992 endingPage "324" @default.
• W2894030992 startingPage "317" @default.
• W2894030992 abstract "Pathological cardiac hypertrophy is the main risk factor for heart diseases. The ubiquitin-proteasome system (UPS) is the major intracellular protein degradation system involved in the development of cardiac hypertrophic remodeling. Ubiquitin-activating enzyme E1, a key component of the UPS, catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation via proteasome. However, the functional role of E1 (UBA1) in regulation of hypertrophic remodeling in angiotensin II (Ang II)-infused mice remains unknown. In this study, male wild-type mice were treated with UBA1 inhibitor PYR-41 at two doses of 5 and 10 mg and infused with Ang II (1000 ng/kg/min) for 14 days. Systolic blood pressure was detected by using tail-cuff system. Cardiac function was assessed by echocardiography. Hypertrophic remodeling was analyzed examined by histological examinations. The expressions of genes and proteins were detected by quantitative real-time PCR and immunoblotting analysis. After 14 days, Ang II infusion significantly increased UBA1 expression at both mRNA and protein levels in the hearts. Furthermore, Ang II-infused mice showed a significant increase in systolic blood pressure compensatory cardiac function, hypertrophy, interstitial fibrosis, inflammation and oxidative stress compared with saline-treated controls, whereas these effects were dose-dependently attenuated in PYR-41-treated mice. These beneficial actions were associated mainly with inhibition of PTEN degradation and multiple downstream mediators (AKT, ERK1/2, STAT3, TGF-β/Smad2/3 and NF-kB(p65)). In conclusion, these results indicate that inhibition of UBA1 suppresses Ang II-induced hypertrophic remodeling, and suggest that administration of low dose PYR-41 may be a new potential therapeutic approach for treating hypertensive heart diseases." @default.
• W2894030992 created "2018-10-05" @default.
• W2894030992 creator A5016329517 @default.
• W2894030992 creator A5028829196 @default.
• W2894030992 creator A5031524039 @default.
• W2894030992 creator A5041772903 @default.
• W2894030992 creator A5049523804 @default.
• W2894030992 creator A5074489669 @default.
• W2894030992 creator A5087264224 @default.
• W2894030992 date "2018-10-01" @default.
• W2894030992 modified "2023-10-16" @default.
• W2894030992 title "Administration of ubiquitin-activating enzyme UBA1 inhibitor PYR-41 attenuates angiotensin II-induced cardiac remodeling in mice" @default.
• W2894030992 cites W135235169 @default.
• W2894030992 cites W1838932899 @default.
• W2894030992 cites W1964229585 @default.
• W2894030992 cites W1979973024 @default.
• W2894030992 cites W1993782756 @default.
• W2894030992 cites W1999353132 @default.
• W2894030992 cites W2014054553 @default.
• W2894030992 cites W2014673395 @default.
• W2894030992 cites W2037202834 @default.
• W2894030992 cites W2040146122 @default.
• W2894030992 cites W2045907417 @default.
• W2894030992 cites W2050862994 @default.
• W2894030992 cites W2052735334 @default.
• W2894030992 cites W2060001443 @default.
• W2894030992 cites W2064711537 @default.
• W2894030992 cites W2070049115 @default.
• W2894030992 cites W2077805564 @default.
• W2894030992 cites W2099002508 @default.
• W2894030992 cites W2116655536 @default.
• W2894030992 cites W2125658800 @default.
• W2894030992 cites W2134802402 @default.
• W2894030992 cites W2147081693 @default.
• W2894030992 cites W2148608806 @default.
• W2894030992 cites W2168664410 @default.
• W2894030992 cites W2202285110 @default.
• W2894030992 cites W2239965295 @default.
• W2894030992 cites W2260361505 @default.
• W2894030992 cites W2264574558 @default.
• W2894030992 cites W2524103344 @default.
• W2894030992 cites W2585223803 @default.
• W2894030992 cites W2725060148 @default.
• W2894030992 cites W2791234633 @default.
• W2894030992 cites W2792454313 @default.
• W2894030992 cites W2804886911 @default.
• W2894030992 cites W2883478139 @default.
• W2894030992 doi "https://doi.org/10.1016/j.bbrc.2018.09.100" @default.
• W2894030992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30249396" @default.
• W2894030992 hasPublicationYear "2018" @default.
• W2894030992 type Work @default.
• W2894030992 sameAs 2894030992 @default.
• W2894030992 citedByCount "11" @default.
• W2894030992 countsByYear W28940309922019 @default.
• W2894030992 countsByYear W28940309922020 @default.
• W2894030992 countsByYear W28940309922021 @default.
• W2894030992 countsByYear W28940309922022 @default.
• W2894030992 countsByYear W28940309922023 @default.
• W2894030992 crossrefType "journal-article" @default.
• W2894030992 hasAuthorship W2894030992A5016329517 @default.
• W2894030992 hasAuthorship W2894030992A5028829196 @default.
• W2894030992 hasAuthorship W2894030992A5031524039 @default.
• W2894030992 hasAuthorship W2894030992A5041772903 @default.
• W2894030992 hasAuthorship W2894030992A5049523804 @default.
• W2894030992 hasAuthorship W2894030992A5074489669 @default.
• W2894030992 hasAuthorship W2894030992A5087264224 @default.
• W2894030992 hasConcept C104317684 @default.
• W2894030992 hasConcept C111566952 @default.
• W2894030992 hasConcept C126322002 @default.
• W2894030992 hasConcept C134018914 @default.
• W2894030992 hasConcept C167414201 @default.
• W2894030992 hasConcept C185592680 @default.
• W2894030992 hasConcept C25602115 @default.
• W2894030992 hasConcept C2776914184 @default.
• W2894030992 hasConcept C2777420927 @default.
• W2894030992 hasConcept C2778198053 @default.
• W2894030992 hasConcept C2779537366 @default.
• W2894030992 hasConcept C2780559512 @default.
• W2894030992 hasConcept C2908929049 @default.
• W2894030992 hasConcept C2992195973 @default.
• W2894030992 hasConcept C55493867 @default.
• W2894030992 hasConcept C71924100 @default.
• W2894030992 hasConcept C84393581 @default.
• W2894030992 hasConcept C86803240 @default.
• W2894030992 hasConceptScore W2894030992C104317684 @default.
• W2894030992 hasConceptScore W2894030992C111566952 @default.
• W2894030992 hasConceptScore W2894030992C126322002 @default.
• W2894030992 hasConceptScore W2894030992C134018914 @default.
• W2894030992 hasConceptScore W2894030992C167414201 @default.
• W2894030992 hasConceptScore W2894030992C185592680 @default.
• W2894030992 hasConceptScore W2894030992C25602115 @default.
• W2894030992 hasConceptScore W2894030992C2776914184 @default.
• W2894030992 hasConceptScore W2894030992C2777420927 @default.
• W2894030992 hasConceptScore W2894030992C2778198053 @default.
• W2894030992 hasConceptScore W2894030992C2779537366 @default.
• W2894030992 hasConceptScore W2894030992C2780559512 @default.
• W2894030992 hasConceptScore W2894030992C2908929049 @default.
• W2894030992 hasConceptScore W2894030992C2992195973 @default.

• next